← Leaderboards
Douglas Brock Cines
Duke University
$21,888,352
Attributed
$27,514,411
Total exposure
15
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,514,411 · 15
By mechanism
R01$11,529,805 · 6
T32$8,492,342 · 1
P01$6,945,079 · 6
R21$426,225 · 1
R03$120,960 · 1
Top collaborators
- Gowthami M Arepally6 shared
- Lubica Rauova6 shared
- David Sullivan Hains4 shared
- Vladimir R Muzykantov4 shared
- Mortimer Poncz4 shared
- Andrew Lawrence Schwaderer4 shared
Most similar at Duke University
Same institution · by research overlap
- Gowthami M Arepally$11,531,413
- Lubica Rauova$2,618,913
- Alisa S Wolberg$13,659,847
- Jennifer M. Wu$814,799
Others in their field
Top investigators on “Thrombosis”
- Paul M. Ridker · Brigham And Women'S Hospital$59,264,235
- John H Griffin · Scripps Research Institute$29,245,116
- David J. Pinsky · University Of Michigan At Ann Arbor$29,054,903
- Bruce Furie · Beth Israel Deaconess Medical Center$28,093,838
- Denisa D Wagner · Boston Children'S Hospital$24,247,974
- Satya P. Kunapuli · Temple University$22,403,131
Research focus
ThrombosisIn VitroIn VivoBasePathogenesisAntibodiesBlood PlateletsHeparinMonocyteInsightBiologicalImmunoglobulin GDiagnosisEpitopesThrombocytopeniaCellsInhibitor/AntagonistPlatelet Factor 4HemorrhageComplementAffinitySpecificityAntigensPlasma
Grant awards (74)
Complement and thrombosis in HIT$799,424
R01 · FY2025 · HL
Complement and Thrombosis in HIT$577,238
R01 · FY2024 · HL
Adrien Jacobs - Undergraduate Research Supplement 5R01-HL151730$11,978
R01 · FY2024 · HL
Complement and Thrombosis in HIT$595,500
R01 · FY2023 · HL
Complement and Thrombosis in HIT$599,600
R01 · FY2022 · HL
Complement and Thrombosis in HIT$633,189
R01 · FY2021 · HL
Genetic Regulation, Tubular Processing and Clinical Relevance of Collecting Duct alpha-Defensins 1-3$579,975
R01 · FY2021 · DK
Structure-based Design of Rational PF4 Inhibitors in HIT$564,008
R01 · FY2021 · HL · contact PI
Genetic Regulation, Tubular Processing and Clinical Relevance of Collecting Duct alpha-Defensins 1-3$586,762
R01 · FY2020 · DK
Structure-based Design of Rational PF4 Inhibitors in HIT$572,191
R01 · FY2020 · HL · contact PI
Structure-based Design of Rational PF4 Inhibitors in HIT$563,808
R01 · FY2019 · HL · contact PI
Genetic Regulation, Tubular Processing and Clinical Relevance of Collecting Duct alpha-Defensins 1-3$549,889
R01 · FY2019 · DK
Genetic Regulation, Tubular Processing and Clinical Relevance of Collecting Duct alpha-Defensins 1-3$598,961
R01 · FY2018 · DK
Structure-based Design of Rational PF4 Inhibitors in HIT$587,000
R01 · FY2018 · HL · contact PI
Training grant in hemostasis and thrombosis$504,574
T32 · FY2018 · HL · contact PI
Training grant in hemostasis and thrombosis$491,761
T32 · FY2017 · HL · contact PI
Pathogenic Antibodies in HIT$518,433
P01 · FY2016 · HL · contact PI
Training grant in hemostasis and thrombosis$489,040
T32 · FY2016 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$401,875
R01 · FY2016 · HL · contact PI
Clinical Samples Core$237,073
P01 · FY2016 · HL · contact PI
Clinical Samples Core$207,709
P01 · FY2016 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$395,846
R01 · FY2015 · HL · contact PI
Training grant in hemostasis and thrombosis$307,162
T32 · FY2015 · HL · contact PI
Pathogenic Antibodies in HIT$288,684
P01 · FY2015 · HL · contact PI
Pathogenic Antibodies in HIT$261,036
P01 · FY2015 · HL · contact PI
Clinical Samples Core$73,040
P01 · FY2015 · HL · contact PI
Clinical Samples Core$73,037
P01 · FY2015 · HL · contact PI
Clinical Samples Core$69,254
P01 · FY2015 · HL · contact PI
Training grant in hemostasis and thrombosis$479,229
T32 · FY2014 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$393,838
R01 · FY2014 · HL · contact PI
Pathogenic Antibodies in HIT$259,441
P01 · FY2014 · HL · contact PI
Pathogenic Antibodies in HIT$259,438
P01 · FY2014 · HL · contact PI
Clinical Samples Core$70,936
P01 · FY2014 · HL · contact PI
Clinical Samples Core$70,936
P01 · FY2014 · HL · contact PI
Clinical Samples Core$70,932
P01 · FY2014 · HL · contact PI
Training grant in hemostasis and thrombosis$579,838
T32 · FY2013 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$396,865
R01 · FY2013 · HL · contact PI
Pathogenic Antibodies in HIT$263,291
P01 · FY2013 · HL · contact PI
Pathogenic Antibodies in HIT$263,287
P01 · FY2013 · HL · contact PI
Clinical Samples Core$70,350
P01 · FY2013 · HL · contact PI
Clinical Samples Core$70,349
P01 · FY2013 · HL · contact PI
Clinical Samples Core$70,348
P01 · FY2013 · HL · contact PI
Training grant in hemostasis and thrombosis$568,770
T32 · FY2012 · HL · contact PI
Pathogenic Antibodies in HIT$339,811
P01 · FY2012 · HL · contact PI
Pathogenic Antibodies in HIT$339,811
P01 · FY2012 · HL · contact PI
Clinical Samples Core$339,809
P01 · FY2012 · HL · contact PI
Clinical Samples Core$339,809
P01 · FY2012 · HL · contact PI
Training grant in hemostasis and thrombosis$550,289
T32 · FY2011 · HL · contact PI
Training Grant in Hemostasis and Thrombosis$341,690
T32 · FY2010 · HL · contact PI
Urokinase, Defensin and Acute Lung Injury$578,158
P01 · FY2009 · HL · contact PI
Training Grant in Hemostasis and Thrombosis$526,235
T32 · FY2009 · HL · contact PI
Urokinase, Defensin and Acute Lung Injury$560,158
P01 · FY2008 · HL · contact PI
Training Grant in Hemostasis and Thrombosis$546,336
T32 · FY2008 · HL · contact PI
Nuclear translocation of urokinase/nucleolin complexes$196,875
R21 · FY2008 · HL · contact PI
Training Grant in Hemostasis and Thrombosis$587,054
T32 · FY2007 · HL · contact PI
Urokinase, Defensin and Acute Lung Injury$443,691
P01 · FY2007 · HL · contact PI
Nuclear translocation of urokinase/nucleolin complexes$229,350
R21 · FY2007 · HL · contact PI
Training Grant in Hemostasis and Thrombosis$474,178
T32 · FY2006 · HL · contact PI
Urokinase, Defensin and Acute Lung Injury$404,383
P01 · FY2006 · HL · contact PI
TRAINING GRANT IN HEMOSTASIS AND THROMBOSIS$470,090
T32 · FY2005 · HL
Urokinase, Defensin and Acute Lung Injury$401,875
P01 · FY2005 · HL
Training Grant in Hemostasis and Thrombosis$518,342
T32 · FY2004 · HL
TRAINING GRANT IN HEMOSTASIS AND THROMBOSIS$550,544
T32 · FY2003 · HL
UROKINASE KRINGLE-MEDIATED VASCULAR REMODELING$40,320
R03 · FY2003 · TW
DEFENSIN AND THE PATHOGENESIS OF ATHEROSCLEROSIS$433,221
R01 · FY2002 · HL
TRAINING GRANT IN HEMOSTASIS AND THROMBOSIS$349,088
T32 · FY2002 · HL
STRUCTURE/FUNCTION ANALYSIS OF THE UROKINASE RECEPTOR$290,520
R01 · FY2002 · HL
UROKINASE KRINGLE-MEDIATED VASCULAR REMODELING$40,320
R03 · FY2002 · TW
DEFENSIN AND THE PATHOGENESIS OF ATHEROSCLEROSIS$423,159
R01 · FY2001 · HL
STRUCTURE/FUNCTION ANALYSIS OF THE UROKINASE RECEPTOR$283,968
R01 · FY2001 · HL
TRAINING GRANT IN HEMOSTASIS AND THROMBOSIS$158,122
T32 · FY2001 · HL
UROKINASE KRINGLE-MEDIATED VASCULAR REMODELING$40,320
R03 · FY2001 · TW
DEFENSIN AND THE PATHOGENESIS OF ATHEROSCLEROSIS$413,386
R01 · FY2000 · HL
STRUCTURE/FUNCTION ANALYSIS OF THE UROKINASE RECEPTOR$277,604
R01 · FY2000 · HL